A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

This study is testing a new type of antibody drug called MOv18 IgE in women with platinum-resistant ovarian cancer whose tumors express a protein called folate receptor alpha (FRα). "Platinum-resistant" means the cancer stopped responding to standard platinum-based chemotherapy. This drug uses a novel approach — it works through the immune system's IgE antibody pathway — which is different from most cancer antibodies currently available. **You may be eligible if...** - You are a woman aged 18 or older - You have advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer of the high-grade serous or endometrioid type - Your tumor has tested positive for the FRα protein (confirmed by biopsy or tissue sample) - Your cancer has continued to grow despite platinum-based chemotherapy - You are in reasonable physical health **You may NOT be eligible if...** - You have never had a tissue sample tested for FRα expression or are unwilling to provide one - You have a known allergy to the study drug components - You have uncontrolled infections or certain serious medical conditions - You have active autoimmune disease or are on immunosuppressive therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.